Seres Therapeutics
MCRB
146 hedge funds and large institutions have $1.93B invested in Seres Therapeutics in 2021 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 56 increasing their positions, 45 reducing their positions, and 27 closing their positions.
685% more call options, than puts
Call options by funds: $46.6M | Put options by funds: $5.94M
24% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 45
4% more capital invested
Capital invested by funds: $1.85B → $1.93B (+$74.6M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.2% less ownership
Funds ownership: 4.92% → 4.71% (-0.2%)
4% less funds holding
Funds holding: 152 → 146 (-6)
22% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$29.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.5M |
| 3 |
Morgan Stanley
New York
|
+$5.78M |
| 4 |
BlackRock
New York
|
+$5.77M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$3.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$45.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$20.1M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
-$15.2M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$13.9M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$8.76M |
MCRB Hedge Fund Activity: Q2 2021 in Review
146 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q2 2021, worth a combined $1.93B — up 4% from $1.85B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of MCRB and 21 opened new positions — a net loss of 6 holders — while 45 trimmed existing stakes and 56 added.
The largest buyer was RA Capital Management, adding an estimated $29.8M. The largest seller was ARK Investment Management, cutting an estimated $45.2M.
- 146 institutional investors held Seres Therapeutics (MCRB) as of Q2 2021, down from 152 in Q1 2021.
- Funds reported $1.93B of Seres Therapeutics stock for Q2 2021, up 4% quarter-over-quarter.
- 21 funds opened new Seres Therapeutics positions in Q2 2021 and 27 closed out, a net change of -6 holders.
- The largest Seres Therapeutics buyer in Q2 2021 was RA Capital Management, an estimated $29.8M added.
- The largest Seres Therapeutics seller in Q2 2021 was ARK Investment Management, an estimated $45.2M sold.
Based on aggregated 13F filings for Q2 2021.